•
Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced a significant global licensing deal with UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). The agreement concerns LM-305, a pre-clinical antibody drug conjugate (ADC) that targets GPRC5D. AstraZeneca will receive exclusive global rights to research, develop, and commercialize LM-305, in…
•
UK major AstraZeneca (AZ, NASDAQ: AZN) has announced that its mitogen-activated protein kinase (MEK) inhibitor, Koselugo (selumetinib), has been approved in China for the treatment of symptomatic, inoperable plexiform neurofibromatosis (PN) in pediatric patients with neurofibromatosis type 1 (NF1) aged three years and above. This marks a significant advancement in…
•
China-based Qilu Pharmaceutical has announced the market launch of its generic version of AstraZeneca’s (AZ, NASDAQ: AZN) first-generation epidermal growth factor receptor (EGFR) inhibitor, Iressa (gefitinib), in the United States. This marks the debut of the first generic version of Iressa in the country, expanding access to this crucial medication…
•
Several multinational companies (MNCs) have released their Q1 2023 financials, showing a varied performance over the quarter. AstraZeneca’s China Innovation BoomAstraZeneca (AZ, NASDAQ: AZN) CEO Pascal Soriot warned that Europe is lagging behind China in fostering innovation and access to medicines. This statement came during the company’s Q1 2023 earnings…
•
Dizal (Jiangsu) Pharmaceutical Co., Ltd (SHA: 688192), the China-based joint venture established by AstraZeneca (AZ, NASDAQ: AZN) and the state-backed Future Industry Investment Fund in October 2017, has announced plans to raise RMB 2.6 billion (USD 376.1 million) through a private placement of 40,815,137 shares. The funds raised will be…
•
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced a partnership with China’s Guangzhou Institute of Respiratory Health National Center for Respiratory Medicine. The collaboration will focus on enhancing efforts in basic medicine, translational medicine, and clinical medical research. The partnership aims to explore the collection and clinical application of…
•
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) and Hong Kong Science and Technology Parks Corp. (HKSTP) have signed a memorandum of understanding (MoU) to strengthen their existing collaboration. This deal builds upon an earlier collaboration signed in February 2021 and will see AstraZeneca and HKSTP supporting and providing services to…
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese vaccine manufacturer, has entered into a strategic partnership with UK-based AstraZeneca (AZ, NASDAQ: AZN) and Indonesian pharmaceutical company Combiphar. The collaboration aims to strengthen the cooperation between China and Indonesia in the vaccine sector. Under the terms of the…
•
At the AstraZeneca’s (AZ, NASDAQ: AZN) R&D China Science Day, Yicai Global reported that the UK-based pharmaceutical giant is planning to triple its investment in research and development in China over the coming months. This strategic move aims to increase the number of innovative drugs entering the Chinese market, as…
•
AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received conditional market approval in China for its next-generation Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib). The drug is approved for the first indication in adults with mantle cell lymphoma (MCL) who have received at least one prior therapy. Clinical Trial…
•
China-based 3SBio Inc. (HKG: 1530) has announced the termination of a distribution agreement with UK major AstraZeneca (AZ, NASDAQ: AZN), effective from December 31, 2023, concerning AstraZeneca’s Byetta (exenatide). The two companies previously entered into a licensing deal focusing on type 2 diabetes therapies, including Byetta and Bydureon (exenatide microspheres).…
•
Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568), has been approved by the National Medical Products Administration (NMPA) for the treatment of unresectable or metastatic HER2-positive adult breast cancer patients who have previously received one or more anti-HER2 drugs.…
•
UK major AstraZeneca’s (AZ, NASDAQ: AZN) blood cancer therapy Calquence (acalabrutinib) was first administered at the Hainan branch of Shanghai’s Ruijin Hospital this week. The drug is being made available ahead of official approval via the Hainan Bo’ao Lecheng medical pilot zone, offering patients early access to this innovative treatment.…
•
China-based firms Lepu Biopharma Co., Ltd (HKG: 2157) and Keymed Biosciences Inc. (HKG: 2162) have jointly announced a licensing agreement with UK major AstraZeneca (AZ, NASDAQ: AZN) for CMG901, a potential first-in-class antibody-drug conjugate (ADC) targeting Claudin 18.2. AstraZeneca is taking on global development, manufacturing, and commercialization rights to the…
•
UK-based multinational AstraZeneca Plc (AZ, NASDAQ: AZN) has released its financial results for the Q4 and full-year 2022 periods. The firm continues to expand at a rapid pace, with total global revenues up 25% year-on-year (YOY) to USD 44.35 billion. This growth is a testament to AstraZeneca’s strong pipeline and…
•
China Meheco Group Co., Ltd (SHA: 600056) announced that its subsidiary Genertec Meheco has entered into a partnership with UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) to handle the import and distribution of Evusheld (tixagevimab, cilgavimab) in mainland China. Evusheld is a COVID-19 prophylactic neutralizing antibody combination designed to provide…
•
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study for its drug candidate SKB264. The antibody-drug conjugate (ADC) targets trophoblast cell-surface antigen 2 (TROP2) and will be evaluated in combination with AstraZeneca’s (AZ, NASDAQ: AZN)…
•
Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb’s (BMS; NYSE: BMY) erythropoietic aid Reblozyl (luspatercept) and BeiGene’s (NASDAQ: BGNE; HKG: 6160; SHA: 688235) Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib), according to Fineline Info & Tech analysis. The approvals mark significant milestones for both drugs…
•
UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has revealed plans to sell Soliris (eculizumab) in Hangzhou for the first time. The drug, originally developed by Alexion Pharmaceuticals, received conditional approval in 2018 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in adults and…
•
UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) released its Q3 2022 earnings report, showing continued growth with a 19% year-on-year (YOY) expansion in product revenues to USD 10.98 billion (all growth figures in constant exchange rate terms). Business Unit PerformanceGrowth was led by the Oncology division, which saw a…